Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with a global annual incidence of nearly 1 million cases. [1] [2] [3] Although the incidence throughout Asia and Africa remains relatively stable, western countries are experiencing a rise in the incidence of this disease. The American Cancer Society surveillance data estimated 18,920 new cases in 2004, representing a significant rise from previous years. 4 It was also estimated that 14,270 deaths occurred as a result of the disease in 2004. Whereas surgical resection presently remains the only curative option for this disease, the majority of patients who undergo resection eventually succumb to the disease. It is clear that novel therapies are needed for the treatment of this aggressive cancer.
Oncolytic herpes simplex viruses (HSV) have recently been shown to be effective in the treatment of a wide variety of human malignancies in animal models including brain, colorectal, lung, gastric, prostate, breast, bladder, and head and neck cancers. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] These attenuated, replication-competent viruses present an exciting new treatment modality in cancer therapy through their ability to selectively replicate within cancer cells while sparing normal cells. 10 This study examines the effectiveness of oncolytic herpes viruses in the treatment of primary hepatocellular carcinoma cell lines in vitro. As such, it provides a framework for in vivo studies investigating the use of an oncolytic herpes virus in the treatment of primary hepatocellular carcinoma. In doing so, we have also established a comprehensive compilation characterizing all known human HCC cell lines.
MATERIAL AND METHODS Cell Lines
All known commercially available human HCC cell lines were studied. Hep 3B2.1-7 (Hep3B, Hep 3B, Hep-3B, HB-8064), Hep G2 (HepG2, HB-8065), PLC/PRF/5 (PLC5, CRL-8024), and SK-HEP-1 (HTB-52) cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA). They were grown in vitro in ATCC medium with phenol red control (Eagle's minimum essential medium with 2 mmol/L L-glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate with 0.1 mmol/L nonessential amino acids, and 1.0 mmol/L sodium pyruvate, 100 U/ml penicillin, and 100 mg/ml streptomycin with 10% fetal calf serum [FCS, Atlanta Biologicals, Norcross, GA]). An additional 12 human HCC cell lines (SNU-182, SNU-354, SNU-368, SNU-387, SNU-398, SNU-423, SNU-449, SNU-475, SNU-739, SNU-761, SNU-878, and SNU-886) were obtained from the Korean Cell Line Bank (KCLB, Seoul, South Korea) and were grown in phenol red controlled RPMI 1640 with 20 mmol/L HEPES, 2.0 g/L sodium bicarbonate, 100 U/ml penicillin and 100mg/ml streptomycin, and 10% FCS. African green monkey kidney cells (Vero cells, ATCC) for viral plaque assays were grown in minimum essential medium containing 10% FCS, 100 U/ml penicillin, and 100mg/ml streptomycin. All cells were maintained in a 5% CO 2 humidified incubator at 37 C.
Virus
G207 is an attenuated, replication-competent, oncolytic herpes simplex virus type-1 (HSV-1) whose construction has been previously described in detail.
14,18 G207, a second-generation virus derived from R3616, a construct by Dr. Roizman (University of Chicago, IL), is attenuated by the deletion of a single copy of the diploid ICP6 gene and deletion of both copies of the g 1 34.5 neurovirulence gene. 14, [18] [19] [20] The virus also contains an insertion of the Escherichia coli b-galactosidase (lacZ) gene into the U L 39 gene that serves as a marker of an infection. 14, 18 Disruption of the U L 39 gene eliminates ribonucleotide reductase activity and increases specificity of the virus for proliferating cells such as tumor cells.
18,21-23 G207 was measured by standard plaque assay as previously described. 14, 17, 18 Cytotoxicity Assay All HCC cell lines were plated at a density of 1 3 10 4 cells per well in 12-well flat-bottom plates (Costar, Corning Inc., Corning, NY) in 1 ml of media. After incubation for 6 hours, G207 (diluted in 50 ml phosphate buffered saline [PBS] ) was added to each well at a multiplicity of infection (MOI, the ratio of viral plaque forming units [pfu] per tumor cell) of three dilutions ranging from 0.01 to 3.0. On days 1, 3, 5, 7, and 9 after infection, supernatant samples were collected and frozen, and wells were washed with PBS. Cells were then lysed with Triton-X (Dow, Midland, MI) (1.35%) to release intracellular lactate dehydrogenase (LDH). LDH was quantified using a Cytotox 96 nonradioactive cytotoxicity assay (Promega, Madison, WI), which is a colorimetric analysis measuring the conversion of a tetrazolium salt into a red formazan product in the presence of LDH. [24] [25] [26] The amount of color formed is directly proportional to the number of lysed cells. Absorbance was measured at 450 nm using a microplate spectrophotometer (EL312e, Bio-Tek Instruments, Winooski, VT). Results are expressed as the surviving fraction of cells as determined by the measured absorbance of each sample relative to control, untreated, cell lysates. All samples were analyzed in triplicate, and each experiment was repeated in triplicate to ensure reproducibility.
Viral Replication Assay
Supernatant samples were collected and frozen from all wells of the cytotoxicity (MOI 0.01, 0.1, and 1.0) experiments (days 1-8) after infection with G207. Vero cells were grown to confluence on 6-well flat-bottom plates (Costar, Corning, Inc.). Supernatant samples were thawed, and serial 10-fold dilutions of the samples were incubated on Vero cells for 4 hours. Wells were then gently washed with media and covered with 1% agarose with media. After 48 hours of incubation, 2 ml of neutral red solution was added, and after an additional 24 hours of incubation, viral plaques were counted. All samples were analyzed in triplicate.
Tumorigenic Assay
Six-week old athymic nude mice (National Cancer Institute, Bethesda, MD) were used to assess tumorigenicity of all HCC cell lines. All animal procedures were performed with the approval of the Memorial Sloan-Kettering Institutional Animal Care and Use Committee. Animals were anesthetized with inhalational isoflurane for all experimental procedures. Flank tumors were established by injection of 1 3 10 7 tumor cells in 50 ml of PBS into the subcutaneous flanks of athymic nude mice. Tumor development and growth was assessed by measuring tumor dimensions 3 times a week. Animals were weighed and monitored closely for signs of distress, including poor grooming, cachexia, respiratory distress, cutaneous ulcerations, or tumor progression. Animals without any evidence of tumor progression or toxicity were monitored for up to 3 months. 
RESULTS

Cell Lines
The hepatocellular carcinoma cell lines Hep3B, HepG2, PLC5, and SK-HEP-1 (ATCC) and SNU-182, SNU-354, SNU-368, SNU-387, SNU-398, SNU-423, SNU-449, SNU-475, SNU-739, SNU-761, SNU-878, and SNU-886 (KCLB) grew readily in culture. Previously determined characteristics of these cell lines, including origin, morphology, hepatitis B virus (HBV) gene integration, the X gene product of the human hepatitis B virus (HBx) DNA status, cellular products, and protein expression, are listed in the Table 1. 27-41
Viral Cytotoxicity
The ability of G207 to kill HCC cell lines was assessed. Three of the four cell lines obtained from the ATCC were sensitive to G207 cytotoxicity. HepG2 and PLC5 demonstrated nearly 100% cell kill by day 7 after infection at an MOI of 1.0 (Fig. 1, A, B) . At an MOI of 0.5, Hep3B similarly showed near-complete cell kill (Fig. 1, C ) . Even at an MOI of 0.1, these three cell lines demonstrated 93.0%, 83.7%, and 83.8% cytotoxicity by day 7, respectively (HepG2, PLC5, Hep3B). In contrast, only SK-HEP-1 was resistant to viral infection with no significant cytotoxicity demonstrated at an MOI as high as 3.0 (Fig. 1, D) .
Four of the 12 HCC cell lines obtained from the KCLB were highly sensitive to G207 cytotoxicity. SNU-182, SNU-387, SNU-886, and SNU-878 demonstrated 71.5%, 59.8%, 65.5%, and 70.4% cell kill, respectively, by day 9 after infection at an MOI of 1.0 (Fig. 2, A-D) . Even at an MOI of 0.01, only 60.6%, 53.4%, 50.4%, and 50.6% of cells, respectively, remained viable by day 9 after infection. Four cell lines demonstrated moderate sensitivity to viral infection. At an MOI of 1.0, SNU-368, SNU-449, SNU-739, and SNU-761 showed 22.4%, 22.4%, 43.2%, and 29.9% cell kill, respectively (Fig. 2, E-H ) . In contrast, the remaining four cell lines of KCLB origin (SNU-398, SNU-475, SNU-354, and SNU-423) were resistant to viral infection with no significant cytotoxicity demonstrated 9 days after infection (Fig. 2, I-L) . 
Viral Replication
The ability of G207 to replicate in human HCC cell lines was also demonstrated. Representative data are shown in Fig. 2 . Hep3B strongly supported logarithmic viral proliferation with peak viral titers measuring 2.5 3 10 5 pfu 5 days after infection, with G207 at an MOI of 0.01 (3 3 10 2 pfu; Fig. 3, A) . This represents a greater than 800-fold amplification of the initial viral dose after 5 days. HepG2 and PLC5 also supported G207 viral replication 7 days after infection at an MOI of 0.1 (3 3 10 3 pfu), demonstrating peak infectious virion recovery of 5 3 10 4 pfu and 2.5 3 10 4 pfu, respectively (Fig. 3, B-C ) .
Tumorigenicity
Tumorigenicity of all 16 HCC cell lines was examined and is listed in the Table 1. 27-41 The ability of Hep3B, PLC5, and SK-Hep1 to form tumors in nude athymic mice was already known from previous reports. failed to develop tumors as long as three months after implantation.
DISCUSSION
Primary HCC is one of the most common malignancies worldwide. [1] [2] [3] There are clear geographic epidemiologic differences, with the highest incidences seen in Asia and Africa. 3, 42, 43 Western countries, however, are experiencing a surge in the incidence of this disease. In the United States, the incidence of HCC increased from 1.4 per 100,000 population in 1980 to 2.4 per 100,000 population in 1995. It further increased to 6.7 per 100,000 population for men and 3.1 for women in the year 2000. 44, 45 In 2004, American Cancer Society surveillance data estimated 18,920 new cases and 14,270 deaths due to HCC. 4 Major risk factors for the development of HCC include chronic hepatitis B and C infection and alcohol consumption, and it is an increase in incidence of these factors that are thought to be responsible for this rise.
In a recent review, median survival of patients who underwent curative resection for HCC was only 39 months, with 1-and 3-year survival rates of 81% and 54%, respectively. 46 In this series, patients who underwent tumor ablation demonstrated a median survival of 15 months with 1-and 3-year survival rates of 56% and 21%, respectively. 46 Patients treated with systemic chemotherapy or supportive care demonstrated a median survival of only 9 months, with a 44% 1-year survival rate and no 3-year survivors. 46 Although hepatic resection remains the best curative option, there are many instances where curative resection cannot be performed, including advanced patient age, underlying severe comorbidities or poor liver function, and locally advanced disease. Whereas numerous alternative treatment modalities have been employed in this setting, including percutaneous microwave coagulation therapy, percutaneous ethanol infusion, regional hyperthermia therapy, and interstitial radiotherapy and radiofrequency interstitial tissue ablation,
none have yet been demonstrated to improve patient survival. [47] [48] [49] [50] [51] [52] [53] It is clear that novel therapies are needed.
Attenuated, replication-competent oncolytic HSV offer an exciting new modality in the armamentarium of anticancer agents. A wealth of recent experiments has demonstrated the effectiveness of these oncolytic herpes viruses in the treatment of a wide variety of human cancer cell lines. We now show that the majority of all known human HCC cell lines are also sensitive to treatment with an oncolytic herpes virus, G207. Eleven of 16 cell lines tested were moderately to highly sensitive to viral infection. In addition, these cell lines also demonstrated the ability to support viral replication, resulting in the exponential amplification of infectious virions. Conversely, five cell lines were resistant to viral infection. Although the mechanism of resistance of cancer cells to viral infection remains largely unknown, our laboratory is actively exploring the genetic and molecular biologic factors thought to be involved.
These viruses have the potential to infect and selectively replicate within cancer cellsdsparing normal cells. 11 The specificity of oncolytic viruses in cancer therapy depends upon an interplay of the intrinsic properties of these viruses and cellular alterations of transformed cells. For example, the second-generation HSV mutant G207, containing mutations in genes required for viral replication including ribonucleotide reductase, is dependent on a high level of homologous host-cell enzymesdcharacteristic of cancer cellsdto complete its lifecycle. 17, 54 The specificity of oncolytic HSV for malignant cellsdsparing normal hepatocytesdin the context of HCC and hepatic metastases has already been explored by our laboratory using an in vivo model of liver regeneration. Delman et al. 55 investigated the ability of normal murine hepatocytes to permit viral replication of G207 after portal administration. Using histochemical staining for the viral marker gene lacZ and immunohistochemical and quantitative polymerase chain reaction-based detection of viral particles, the authors demonstrated no measurable viral presence or replication in normal, resting murine hepatocytes. Interestingly, this work did show that regenerating hepatocytes were capable of supporting viral replication during peak hepatocyte DNA synthesis after partial hepatectomy. The authors further demonstrated that this period of permissive viral replication correlated with up-regulated hepatocyte ribonucleotide reductase activitydthe viral homologue of which is deleted from G207 for attenuation. Viral administration immediately after resolution of liver regeneration, as early as 7 days after hepatectomy, resulted in no measurable viral replication in the liver or any other organ. Although the maximum clinically achievable MOI in humans is not well-defined, it is generally thought that it approaches 1.0. More important, however, is the potential for in vivo amplification of the administered dose of this novel form of therapydunlike all other standard therapies. As such, delivery of large initial doses is not necessary. Successful completion of the viral life cycle within cancer cells, in addition to causing cell death via lysis or apoptosis, results in the extracellular release of infectious viral progeny, and hence, an exponential amplification of the effective dose. Viral amplification is limited only to the extent that there are viable cancer cells present to support viral replication. Several human clinical trials investigating the use of oncolytic herpes viruses as anticancer agents have begun to answer this question. A phase I trial from our institution was the first to demonstrate that oncolytic herpes viruses can be safely injected into the bloodstream of patients with colorectal hepatic metastases. 56 The maximum therapeutic dose was not reached but was determined to be greater than 1.3 3 10 7 pfu. 56 In a phase I trial investigating the effectiveness of G207 in the treatment of recurrent gliomas, investigators delivered a maximum dose of 3 3 10 9 pfu directly into tumors. 57, 58 Current management of HCC is inadequate, and alternative treatment options are needed. Oncolytic herpes viruses have already been demonstrated to be effective in the treatment of colorectal liver metastases via portal and hepatic arterial delivery in animal models, and human clinical trials are presently ongoing. This work provides a framework for future studies exploring the in vivo effectiveness of oncolytic HSV as potential therapy for patients with HCC.
CONCLUSIONS
This study demonstrates that an oncolytic herpes virus effectively infects, replicates within, and lyses the majority of all known HCC cell lines. We suggest from this data that oncolytic HSV therapy may have a role in the treatment of HCC in the future. Additionally, this compilation of all commercially available HCC cell lines can be used to guide further in vitro and in vivo experiments for the treatment of HCC by using oncolytic herpes viruses and other experimental treatment modalities.
